ArticleClinical and translational gastroenterology2014
Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps.
Article in Clinical and translational gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342440 (A Liquid Biopsy Assay For The Non-Invasive Early Detection of Advanced Adenomas and Colorectal Cancer), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Liquid Biopsy Assay For The Non-Invasive Early Detection of Advanced Adenomas and Colorectal Cancer
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Pooled it
- Pooled it
- Integrative Multi-Omics Analysis Reveals the Characteristic Metabolic Signature of Glioma and Enables Plasma-Based Liquid Biopsy.Research (Washington, D.C.) · 2026Article
- Understanding colorectal cancer-related stigma and its impact on cancer survivors in South-West Nigeria: a qualitative study of patients, caregivers, and healthcare professionals.Journal of cancer survivorship : research and practice · 2025Article
- Cracking the Code of Colorectal Cancer Screening: An Overview With a Focus on Current and Emerging Screening Methods.Cureus · 2025Review
- Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Molecular cancer · 2024Review
- Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection.NPJ precision oncology · 2024Article
- NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection.Nature communications · 2024Article
- Identification of urinary biomarkers of colorectal cancer: Towards the development of a colorectal screening test in limited resource settings.Cancer biomarkers : section A of Disease markers · 2023Article
- Urine NMR Metabolomics for Precision Oncology in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Optimal Strategies for Colorectal Cancer Screening.Current treatment options in oncology · 2022Review
- When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective.Frontiers in oncology · 2022Review
- Comprehensive Volatilome and Metabolome Signatures of Colorectal Cancer in Urine: A Systematic Review and Meta-Analysis.Cancers · 2021Review
- Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review.Cancers · 2021Review
- Metabolite profile comparisons between ascending and descending colon tissue in healthy adults.World journal of gastroenterology · 2020Article
- Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies.International journal of colorectal disease · 2019Article
- Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.The EPMA journal · 2018Article
- Review
- Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer.Molecular and clinical oncology · 2017Article
- Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps.Metabolites · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAdenomatous polyps are precursors of colorectal cancer; their detection and removal is the goal of colon cancer screening programs. However, fecal-based methods identify patients with adenomatous polyps with low levels of sensitivity. The aim or this study was to develop a highly accurate, prototypic, proof-of-concept, spot urine-based diagnostic test using metabolomic technology to distinguish persons with adenomatous polyps from those without polyps.
methodsProspective urine and stool samples were collected from 876 participants undergoing colonoscopy examination in a colon cancer screening program, from April 2008 to October 2009 at the University of Alberta. Colonoscopy reference standard identified 633 participants with no colonic polyps and 243 with colonic adenomatous polyps. One-dimensional nuclear magnetic resonance spectra of urine metabolites were analyzed to define a diagnostic metabolomic profile for colonic adenomas. A urine metabolomic diagnostic test for colonic adenomatous polyps was established using 67% of the samples (un-blinded training set) and validated using the other 33% of the samples (blinded testing set). The urine metabolomic diagnostic test's specificity and sensitivity were compared with those of fecal-based tests.
resultsUsing a two-component, orthogonal, partial least-squares model of the metabolomic profile, the un-blinded training set identified patients with colonic adenomatous polyps with 88.9% sensitivity and 50.2% specificity. Validation using the blinded testing set confirmed sensitivity and specificity values of 82.7% and 51.2%, respectively. Sensitivities of fecal-based tests to identify colonic adenomas ranged from 2.5 to 11.9%.
conclusionsWe describe a proof-of-concept spot urine-based metabolomic diagnostic test that identifies patients with colonic adenomatous polyps with a greater level of sensitivity (83%) than fecal-based tests.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.